retatrutide parkinson's disease trial nct parkinson Retatrutide Dosing: Early Clinical Trial Insights on How It Might Work Triple hormone receptor agonist retatrutide

It also slows gastric emptying, meaning food stays in your stomach longer, which contributes to the feeling of fullness

Effects of empagliflozin on progression of chronic kidney disease: a prespecified secondary analysis from the EMPA-kidney trial

No all-day trips to the doctor's office, no risk of getting sick in a waiting room, no calling off work to make time for an appointment, just a quick and easy process using modern technology

GLP-1 RA glucagon-like peptide 1 receptor agonists, CI confidence interval, MACE major adverse cardiovascular event, MI myocardial infarction, SBP systolic blood pressure in mmHg, HR hazard ratio, RR relative risk, HF heart failure, LVEF left-ventricular ejection fraction a Primary or secondary outcome of interest as reported by the study Statistically significant confidence interval Major Adverse Cardiac Events Among Patients with T2DM Strong evidence supports using GLP-1 RAs to reduce MACE among patients with T2DM and established CVD

doi: 10.3389/fonc.2026.1834606 Received 19 March 2026 Revised 09 May 2026 Accepted 13 May 2026 Published 28 May 2026 Volume 16 - 2026 Edited by Fahui Liu, Xiamen University, China Reviewed by Armando Patrizio, Memorial Sloan Kettering Cancer Center, NY, United States Qiming Gong, Affiliated Hospital of Youjiang Medical University for Nationalities, China Hao Ling, Technical University of Munich, Germany Updates Copyright 2026 Kennedy, Thomas, DArcy, Odia, Kamdar, Pereira, Scarola, Miles, Frank, Taneja, Seetharamu and Mandal